Benzinga | Jul 30, 2020 04:27PM EDT

Aimmune Therapeutics Q2 EPS $(1.06) Beats $(1.09) Estimate

Aimmune Therapeutics (NASDAQ:AIMT) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.09) by 2.75 percent. This is a 4.95 percent decrease over losses of $(1.01) per share from the same period last year.